Topic

All

15
Jul
2020

Do We Need Models Anymore?

Long ago, in the early days of the pandemic, models were everywhere in the news. As our lives were upended and everything became uncertain, models were there to provide some predictability in the face of the unknown. Never mind that predictions varied wildly – between models, and even within the same model at different time points. The models agreed that...
Read More
13
Jul
2020

Playing the Long Game for Antibiotic R&D

This week’s unveiling of the AMR Action Fund, a $1 billion public/private consortium anchored by 23 pharmaceutical companies to support the development and commercialization of antibiotics, is a welcome development in the fight against antimicrobial resistant infections.   The money is important, but it was very encouraging to see the leadership of major pharmaceutical companies — Pfizer, Merck, and Eli...
Read More
11
Jul
2020

Can Novartis Digitally Transform Clinical Development?

In 2018, Dr. Vas Narasimhan, newly-installed as CEO, told the Wall Street Journal he saw Novartis as “a focused medicines company that’s powered by data science and digital technologies.”  Since then, Novartis has tried to grow into this ambition, embracing the concept of digital transformation perhaps more conspicuously than any other large pharma.  It’s not easy, as Narasimhan himself acknowledged...
Read More
10
Jul
2020

The Remdesivir Pricing Letter Gilead Should Have Written

Dear America, We’ve decided to grossly underprice remdesivir. Hundreds of thousands of COVID-19 patients in America, and even more around the world, need our drug. But the US insurance system is corrupt and heartless. It has demonstrated that it will go to great lengths to prevent patients from getting appropriate, physician-prescribed treatments. You know their tricks: high deductibles, high copays,...
Read More
25
Jun
2020

The Exponential Curves Re-Emerge

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.   Subscribe Now   Sign in to your account.
22
Jun
2020

From Heart to Head, Corporations Can Step Up Against Systemic Racism 

The raw, painful emotions emanating from Minneapolis, in the aftermath of George Floyd’s killing by police, have prompted millions of people to stand up in defiance of racism and inequality. The passionate reaction is right, and long overdue. George Floyd was just the latest in a terrible list of victims of police brutality. What’s most important is how activists have...
Read More